Sigma-Aldrich收购Olink Bioscience的Duolink 产品业务

ST. LOUIS, Oct. 29, 2015 /PRNewswire/ -- Sigma-Aldrich Corporation (NASDAQ: SIAL), a leading Life Science and Technology company, today announced that it has signed an agreement to acquire the Duolink^® product portfolio from Olink Bioscience. The acquisition includes intellectual property, sales, marketing and manufacturing assets.

The newly acquired product line is designed for researchers studying biological pathways and seeking improved sensitivity to uncover disease biomarkers. Since 2013, Sigma-Aldrich has distributed Duolink reagents, along with pre-validated antibody pairs for proximity ligation assays (in situ PLA^®).

"We are excited about the acquisition of the Duolink product portfolio. Duolink is valuable to our customers and complements the rest of Sigma-Aldrich's Protein Biology portfolio," said  Amanda Halford, Vice President, Academic Research at Sigma-Aldrich.  "Owning the Duolink technology will provide Sigma-Aldrich with opportunities to develop new products, as well as advance our existing technologies."

Duolink Technology, based on PLA technology, enables researchers to visualize low levels of proteins, protein modifications and individual protein interactions directly in fixed cells and tissue samples without the need for overexpression. This technology can significantly enhance the rigor and reproducibility of scientific experiments, aided by dual recognition of antibody pairs.

"Duolink has been a very important product in the history and development of Olink, and we feel that with this acquisition by Sigma-Aldrich, it will be in very good hands and continue to be a great success," said  Jon Heimer, CEO of Olink Bioscience. "We will now focus our resources on further developing our Proseek^® Multiplex product line for human protein biomarker research, as well as expanding our global presence by establishing local commercial organizations in Europe and North America, and continuing to develop new innovative tools for the scientific community."

"Duolink technology is transforming the way scientists study biological pathways. It allows interactions between proteins at the endogenous levels to now be visualized, providing researchers with reproducible data they can see," said Halford. "The acquisition of Duolink allows Sigma-Aldrich to provide comprehensive solutions for enabling experimental reproducibility, with continued reliability in supply and quality."

Cautionary Statement: The foregoing release contains forward-looking statements that can be identified by terminology such as "will provide," "will advance," "will allow" or similar expressions, or by expressed or implied discussions regarding potential future revenues from products derived there from. You should not place undue reliance on these statements. Such forward-looking statements reflect the current views of management regarding future events, and involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no guarantee that this or any other product offering will assist the Company to achieve any particular levels of revenue in the future. In particular, management's expectations regarding this product offering could be affected by, among other things, the Company's ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry and general public pricing pressures; the impact that the foregoing factors could have on the values attributed to the Company's assets and liabilities as recorded in its consolidated balance sheet, and other risks and factors referred to in Sigma-Aldrich's current Form 10-K on file with the US Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those anticipated, believed, estimated or expected. Sigma-Aldrich is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.

About Sigma-Aldrich:  Sigma-Aldrich, a leading Life Science and Technology company focused on enhancing human health and safety, manufactures and distributes 250,000 chemicals, biochemicals and other essential products to more than 1.4 million customers globally in research and applied labs as well as in industrial and commercial markets. With three distinct business units - Research, Applied and SAFC Commercial - Sigma-Aldrich is committed to enabling science to improve the quality of life. The Company operates in 37 countries, has approximately 9,700 employees worldwide and had sales of $2.79 billion in 2014. For more information about Sigma-Aldrich, please visit its website at www.sigma-aldrich.com .

Sigma-Aldrich and Sigma are trademarks of Sigma-Aldrich Co, LLC registered in the US and other countries.

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/sigma-aldrich-acquires-duolink-product-portfolio-from-olink-bioscience-300168400.html

SOURCE Sigma-Aldrich